MedTrace Logo

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

NCT03827668 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-05-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.

Conditions

  • Healthy

Interventions

DRUG

PF-06650833 alone

In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.

DRUG

PF-06651600 alone

In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.

DRUG

PF-06650833 together with PF-06651600

In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-07
Primary Completion
2019-04-29
Completion
2019-04-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03827668 on ClinicalTrials.gov